Last reviewed · How we verify
Levofloxacin + Ceftriaxone
This combination uses a fluoroquinolone antibiotic to inhibit bacterial DNA gyrase and topoisomerase IV, while a third-generation cephalosporin inhibits bacterial cell wall synthesis, providing broad-spectrum coverage against gram-positive and gram-negative bacteria.
This combination uses a fluoroquinolone antibiotic to inhibit bacterial DNA gyrase and topoisomerase IV, while a third-generation cephalosporin inhibits bacterial cell wall synthesis, providing broad-spectrum coverage against gram-positive and gram-negative bacteria. Used for Community-acquired pneumonia, Complicated urinary tract infections, Intra-abdominal infections.
At a glance
| Generic name | Levofloxacin + Ceftriaxone |
|---|---|
| Sponsor | Bayer |
| Drug class | Fluoroquinolone + Third-generation cephalosporin combination |
| Target | Bacterial DNA gyrase, topoisomerase IV, penicillin-binding proteins |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Levofloxacin is a fluoroquinolone that disrupts bacterial DNA replication by inhibiting topoisomerases, while ceftriaxone is a beta-lactam antibiotic that binds penicillin-binding proteins and prevents peptidoglycan cross-linking in the bacterial cell wall. Together, they provide synergistic bactericidal activity against a wide range of aerobic and some anaerobic pathogens, reducing the likelihood of resistance development.
Approved indications
- Community-acquired pneumonia
- Complicated urinary tract infections
- Intra-abdominal infections
- Bacterial infections requiring broad-spectrum coverage
Common side effects
- Nausea
- Diarrhea
- Headache
- Tendinitis/tendon rupture (fluoroquinolone-associated)
- QT prolongation
- Hypersensitivity reactions (cephalosporin-associated)
Key clinical trials
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
- A Platform Trial for Gram Negative Bloodstream Infections (NA)
- Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2) (PHASE3)
- STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis (PHASE3)
- Early Antibiotics After Aspiration in ICU Patients (PHASE4)
- Comparison Between Effect of Empirical Antibiotic Prophylaxis Versus Enhanced Prophylactic Measures on Rate of Urinary Tract Infection After Flexible Ureteroscopy in Children With Pyuria (PHASE2, PHASE3)
- BALANCE+ Vanguard Phase (NA)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levofloxacin + Ceftriaxone CI brief — competitive landscape report
- Levofloxacin + Ceftriaxone updates RSS · CI watch RSS
- Bayer portfolio CI